Nøkkelinformasjon ved kontantutbytte for Wilson ASA
Styret i Wilson har besluttet å foreslå for generalforsamlingen et utbytte NOK 3,0 per aksje for 2022.
* Utbyttebeløp: 3,0
* Annonsert valuta: NOK
* Siste dag inklusive: 30. mars 2023
* Ex-dato: 31. mars 2023
* Record date (eierregisterdato): 3. april 2023
* Betalingsdato: 19. april 2023
* Vedtaksdato: 6. mars 2023
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.
Om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeldinger fra GlobeNewswire by notified
Registrer deg med din e-postadresse under for å få de nyeste sakene fra GlobeNewswire by notified på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra GlobeNewswire by notified
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that
Inventiva reports its 2022 full-year results29.3.2023 22:00:00 CEST | Press release
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva received the first tranche of €25 million under its credit facility with the European Investment Bank (EIB) Screening of the first patients in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D Secured a new patent expanding the IP protection of lanifibranor in the U.S. In January 2023, Inventiva announced changes to NATiV3, a Phase III trial with lanifibranor in patients with NASH, that are expected to be beneficial to the clinical program Daix (F
Nova Klúbburinn hf.: Niðurstöður aðalfundar þann 29. mars 202329.3.2023 21:54:28 CEST | Press release
Aðalfundur Nova Klúbbsins hf. var haldinn í dag, miðvikudaginn, 29. mars 2023. Þetta var fyrsti aðalfundur í skráðu félagi sem eingöngu var stýrt af konum en Hrund Rudolfsdóttir flutti skýrslu stjórnar, Margrét Tryggvadóttir skemmtana- & forstjóri fór yfir árið, Svanhildur Magnúsdóttir var fundarstjóri og ritari fundar var Ásta Guðjónsdóttir. Í stjórn félagsins voru kjörnir eftirfarandi einstaklingar: Hrund Rudolfsdóttir Jón Óttar Birgisson Jóhannes Þorsteinsson Magnús Árnason Sigríður Olgeirsdóttir Jóhannes, Sigríður og Magnús koma inn í stjórnina í stað Hugh Short, Kevin Payne og Tinu Pidgeon. Stjórn hefur skipt með sér verkum og var Sigríður Olgeirsdóttir kjörinn formaður stjórnar. Jóhannes Þorsteinsson starfar í dag sem yfirmaður fjárstýringar T-Mobile í Bandaríkjunum, þar sem hann ber ábyrgð á allri fjármögnun fyrirtækisins. T-Mobile er leiðandi fyrirtæki á fjarskiptamarkaði í Ameríku. Sigríður Olgeirsdóttir er reyndur stjórnandi í hugbúnaðar- og hátæknigeiranum. Magnús er sjálfst
Orkuveita Reykjavíkur – Green Bond Offering Results29.3.2023 20:44:54 CEST | Press release
Today, March 30th, Orkuveita Reykjavíkur (OR; Reykjavik Energy) concluded a closed green bond offering in series OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued with a nominal value of ISK 12,617 million in the category. The series attracted bids totalling ISK 2,160 million nominal value at yields between 3.17% and 3.35%. OR accepted bids amounting to ISK 1,960 million at a yield of 3.24%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds have been issued with a nominal value of ISK 22,601 million in the category. The series attracted bids totalling ISK 820 million nominal value at yields between 2.99% and 3.15%. OR accepted bids amounting to ISK 620 million at a yield of 3.04%. Fossar Investment Bank oversees the issuance and sale of the b